ClinicalTrials.gg
CompletedNCT00734097NEONUpdated Oct 10, 2012Results posted

A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)

A Phase 4 interventional study of Esomeprazole 40 mg and Physical Exam in Gastroesophageal Reflux Disease, sponsored by AstraZeneca. Completed at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-10-10.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing esomeprazole in Gastroesophageal Reflux — 1 open to participants now, 1 under way, none of them phase 3. Esomeprazole · Gastroesophageal Reflux.

Enrollment
22nd of 66
314 · median 125
Started
2007
with 2 others
Phase 4
28 of 67
none open now
Registered
45th of 67
by date
Lead sponsor
36 of 67
AstraZeneca

Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, this one is the 22nd largest by enrollment of the 66 interventional ones that give a count, is one of 3 that started in 2007, is one of 28 in phase 4, and was the 45th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

1 of the 67 studies testing esomeprazole in Gastroesophageal Reflux is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing esomeprazole in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a change in treatment.

03

Conditions studied

  • Gastroesophageal Reflux Disease

Keywords

  • heartburn
  • reflux
  • proton
  • pump
  • inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Persisting symptoms of GORD despite previous treatment with a full dose proton pump inhibitor
  • over 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Current course of Proton Pump inhibitor treatment for more than 8 weeks prior to enrolment in the study
  • More than 1 other course of PPI treatment in the previous 12 month
  • previous use of esomeprazole
  • presence of alarm symptoms
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
314 participants (actual)

Study arms

  • Experimental
    Nexium 40 mgs

    Drug: Esomeprazole 40 mg · Procedure: Physical Exam · Other: Quality of Life Questionnaires · Procedure: pregnancy test, if applicable

Interventions

  • Once a day

    Also known as: Nexium

  • ProcedurePhysical Exam

    every visit

  • OtherQuality of Life Questionnaires

    every visit

  • Procedurepregnancy test, if applicable

    as needed

06

What researchers measure

Primary outcomes

  1. Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment

    Reported frequency of days with heartburn at week 8 - reported frequency of days with heartburn at baseline

    Time frame: At Baseline and 8 weeks

Secondary outcomes

  1. Change in Frequency of Days With Heartburn From Baseline to 4 Weeks of Treatment

    Reported frequency of days with heartburn at week 4 - reported frequency of days with heartburn at baseline.

    Time frame: At Baseline and 4 weeks

  2. Change in Severity of Heartburn From Baseline to 8 Weeks of Treatment

    Reported severity of heartburn at week 8 on RDQ - reported severity of heartburn at baseline on RDQ RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

    Time frame: At Baseline and 8 weeks

  3. Change in Severity of Heartburn From Baseline to 4 Weeks of Treatment

    Reported severity of heartburn at week 4 on RDQ - reported severity of heartburn at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

    Time frame: At Baseline and 4 weeks

  4. Change in Frequency of Days With Acid Regurgitation From Baseline to 4 Weeks of Treatment.

    Reported frequency of days with Acid regurgitation at week 4 - reported frequency of days with acid regurgitation at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

    Time frame: At Baseline and 4 weeks.

  5. Change in Frequency of Days With Acid Regurgitation From Baseline to 8 Weeks of Treatment.

    Reported frequency of days with Acid regurgitation at week 8 - reported frequency of days with acid regurgitation at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

    Time frame: At Baseline and 8 weeks.

  6. Change in Frequency of Epigastric Pain After 4 Weeks of Treatment

    Reported frequency of days with Epigastric Pain at week 4 - reported frequency of days with Epigastric Pain at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

    Time frame: At Baseline and 4 weeks

  7. Change in Frequency of Epigastric Pain After 8 Weeks of Treatment

    Reported frequency of days with Epigastric Pain at week 8 - reported frequency of days with Epigastric Pain at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension were range from 0 to 5 for frequency (not present to daily) and severity (not present to severe).

    Time frame: At Baseline and 8 weeks

  8. Change in Severity of Epigastric Pain After 8 Weeks of Treatment

    Reported severity of epigastric pain at week 8 on RDQ - reported severity of epigastric pain at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

    Time frame: At Baseline and 8 weeks

  9. Change in Severity of Epigastric Pain After 4 Weeks of Treatment

    Reported severity of epigastric pain at week 4 on RDQ - reported severity of epigastric pain at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

    Time frame: At Baseline and 4 weeks

  10. Change in Severity of Acid Regurgitation After 8 Weeks of Treatment

    Reported severity of acid regurgitation at week 8 on RDQ - reported severity of acid regurgitation at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

    Time frame: At Baseline and 8 weeks

  11. Change in Severity of Acid Regurgitation After 4 Weeks of Treatment

    Reported severity of acid regurgitation at week 4 on RDQ - reported severity of acid regurgitation at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

    Time frame: At Baseline and 4 weeks

07

Results

Posted Oct 10, 2012

Participant flow

Participants with persisting symptoms of Gastroesophageal Reflux Disease (GORD) despite previous treatment with a full dose proton pump inhibitor were enrolled across the Argentina (6 sites), Chile (3 sites) Colombia (9 sites) and Venezuela (2 sites).

Screening
Participant flow — Screening
MilestoneEsomeprazole 40mg, Daily
Started337
Completed317
Not completed20
Withdrew: Protocol violation12
Withdrew: Withdrawal by subject5
Withdrew: Lost to follow-up2
Withdrew: Unconfirmed pregnancy1
Open Label
Participant flow — Open Label
MilestoneEsomeprazole 40mg, Daily
Started317
Safety analysis317
Full analysis311
Per protocol301
Completed301
Not completed16
Withdrew: Lost to follow-up7
Withdrew: Withdrawal by subject5
Withdrew: Protocol violation4

Outcome measures

PrimaryChange in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment

Reported frequency of days with heartburn at week 8 - reported frequency of days with heartburn at baseline

Time frame:
At Baseline and 8 weeks
Reported as:
Mean · Days per week with symptoms
Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment
Days per week with symptomsEsomeprazole 40mg, Daily
Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment-3.44 ± 2.35
SecondaryChange in Frequency of Days With Heartburn From Baseline to 4 Weeks of Treatment

Reported frequency of days with heartburn at week 4 - reported frequency of days with heartburn at baseline.

Time frame:
At Baseline and 4 weeks
Reported as:
Mean · Days per week with symptoms
Change in Frequency of Days With Heartburn From Baseline to 4 Weeks of Treatment
Days per week with symptomsEsomeprazole 40mg, Daily
Change in Frequency of Days With Heartburn From Baseline to 4 Weeks of Treatment-3.08 ± 2.32
SecondaryChange in Severity of Heartburn From Baseline to 8 Weeks of Treatment

Reported severity of heartburn at week 8 on RDQ - reported severity of heartburn at baseline on RDQ RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

Time frame:
At Baseline and 8 weeks
Reported as:
Mean · Units of scale
Change in Severity of Heartburn From Baseline to 8 Weeks of Treatment
Units of scaleEsomeprazole 40mg, Daily
Change in Severity of Heartburn From Baseline to 8 Weeks of Treatment-1.56 ± 1.01
SecondaryChange in Severity of Heartburn From Baseline to 4 Weeks of Treatment

Reported severity of heartburn at week 4 on RDQ - reported severity of heartburn at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

Time frame:
At Baseline and 4 weeks
Reported as:
Mean · Units on scale
Change in Severity of Heartburn From Baseline to 4 Weeks of Treatment
Units on scaleEsomeprazole 40mg, Daily
Change in Severity of Heartburn From Baseline to 4 Weeks of Treatment-1.34 ± 1.03
SecondaryChange in Frequency of Days With Acid Regurgitation From Baseline to 4 Weeks of Treatment.

Reported frequency of days with Acid regurgitation at week 4 - reported frequency of days with acid regurgitation at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

Time frame:
At Baseline and 4 weeks.
Reported as:
Mean · Days per week with symptoms
Change in Frequency of Days With Acid Regurgitation From Baseline to 4 Weeks of Treatment.
Days per week with symptomsEsomeprazole 40mg, Daily
Change in Frequency of Days With Acid Regurgitation From Baseline to 4 Weeks of Treatment.-2.95 ± 2.42
SecondaryChange in Frequency of Days With Acid Regurgitation From Baseline to 8 Weeks of Treatment.

Reported frequency of days with Acid regurgitation at week 8 - reported frequency of days with acid regurgitation at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

Time frame:
At Baseline and 8 weeks.
Reported as:
Mean · Days per week with symptoms
Change in Frequency of Days With Acid Regurgitation From Baseline to 8 Weeks of Treatment.
Days per week with symptomsEsomeprazole 40mg, Daily
Change in Frequency of Days With Acid Regurgitation From Baseline to 8 Weeks of Treatment.-3.28 ± 2.51
SecondaryChange in Frequency of Epigastric Pain After 4 Weeks of Treatment

Reported frequency of days with Epigastric Pain at week 4 - reported frequency of days with Epigastric Pain at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

Time frame:
At Baseline and 4 weeks
Reported as:
Mean · Days per week with pain
Change in Frequency of Epigastric Pain After 4 Weeks of Treatment
Days per week with painEsomeprazole 40mg, Daily
Change in Frequency of Epigastric Pain After 4 Weeks of Treatment-2.77 ± 2.5
SecondaryChange in Frequency of Epigastric Pain After 8 Weeks of Treatment

Reported frequency of days with Epigastric Pain at week 8 - reported frequency of days with Epigastric Pain at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension were range from 0 to 5 for frequency (not present to daily) and severity (not present to severe).

Time frame:
At Baseline and 8 weeks
Reported as:
Mean · Days per week with pain
Change in Frequency of Epigastric Pain After 8 Weeks of Treatment
Days per week with painEsomeprazole 40mg, Daily
Change in Frequency of Epigastric Pain After 8 Weeks of Treatment-3.16 ± 2.52
SecondaryChange in Severity of Epigastric Pain After 8 Weeks of Treatment

Reported severity of epigastric pain at week 8 on RDQ - reported severity of epigastric pain at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

Time frame:
At Baseline and 8 weeks
Reported as:
Mean · Units of scale
Change in Severity of Epigastric Pain After 8 Weeks of Treatment
Units of scaleEsomeprazole 40mg, Daily
Change in Severity of Epigastric Pain After 8 Weeks of Treatment-1.34 ± 1.1
SecondaryChange in Severity of Epigastric Pain After 4 Weeks of Treatment

Reported severity of epigastric pain at week 4 on RDQ - reported severity of epigastric pain at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

Time frame:
At Baseline and 4 weeks
Reported as:
Mean · Units of scale
Change in Severity of Epigastric Pain After 4 Weeks of Treatment
Units of scaleEsomeprazole 40mg, Daily
Change in Severity of Epigastric Pain After 4 Weeks of Treatment-1.17 ± 1.1
SecondaryChange in Severity of Acid Regurgitation After 8 Weeks of Treatment

Reported severity of acid regurgitation at week 8 on RDQ - reported severity of acid regurgitation at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

Time frame:
At Baseline and 8 weeks
Reported as:
Mean · Units of scale
Change in Severity of Acid Regurgitation After 8 Weeks of Treatment
Units of scaleEsomeprazole 40mg, Daily
Change in Severity of Acid Regurgitation After 8 Weeks of Treatment-1.51 ± 1.09
SecondaryChange in Severity of Acid Regurgitation After 4 Weeks of Treatment

Reported severity of acid regurgitation at week 4 on RDQ - reported severity of acid regurgitation at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).

Time frame:
At Baseline and 4 weeks
Reported as:
Mean · Units of scale
Change in Severity of Acid Regurgitation After 4 Weeks of Treatment
Units of scaleEsomeprazole 40mg, Daily
Change in Severity of Acid Regurgitation After 4 Weeks of Treatment-1.31 ± 1.06

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Esomeprazole 40mg, Daily—4/317 (1.3%)16/317 (5%)
Most frequent serious events
Most frequent serious events
EventEsomeprazole 40mg, Daily
Dizziness / Hypotension / TachycardiaCardiac disorders1/317
Gastric CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/317
Vaginal haemorrhageReproductive system and breast disorders1/317
Uterine LeiomyomaReproductive system and breast disorders1/317
Most frequent other events
Most frequent other events
EventEsomeprazole 40mg, Daily
HeadacheNervous system disorders16/317

Baseline characteristics

Age Continuous
Age Continuous(Years)Esomeprazole 40mg, Daily
Mean42.7 ± 14.3
Sex: Female, Male
Sex: Female, Male(Participants)Esomeprazole 40mg, Daily
Female212
Male99
08

Study locations

10 sites
  • Research Site
    Buenos Aires, Argentina
  • Research Site
    Santiago de Chile, Chile
  • Research Site
    Temuco, Chile
  • Research Site
    Vina del Mar, Chile
  • Research Site
    Barranquilla, Colombia
  • Research Site
    Bogota, Colombia
  • Research Site
    Medellin, Colombia
  • Research Site
    Barquisimeto, Venezuela
  • Research Site
    Caracas, Venezuela
  • Research Site
    San Cristobal, Venezuela
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2008
First posted
Aug 13, 2008
Start
Nov 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Oct 10, 2012
Last update
Oct 10, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00734097
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 13, 2008
Start date
Nov 2007
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Oct 10, 2012
Last update
Oct 10, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion